Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 11/20 | 0.89 |
| ▸ | TEK | Q02763 | 7/20 | 0.89 |
| ▸ | ERBB2 | P04626 | 6/20 | 0.89 |
| ▸ | ERBB3 | P21860 | 6/20 | 0.89 |
| ▸ | ERBB4 | Q15303 | 6/20 | 0.89 |
| ▸ | EIF2AK3 | Q9NZJ5 | 6/20 | 0.46 |
| ▸ | KDR | P35968 | 3/20 | 0.45 |
| ▸ | ABL1 | P00519 | 5/20 | 0.45 |
| ▸ | SRC | P12931 | 5/20 | 0.45 |
| ▸ | ABL2 | P42684 | 5/20 | 0.45 |
| ▸ | RET | P07949 | 2/20 | 0.45 |
| ▸ | LCK | P06239 | 2/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.45 |
| ▸ | INSR | P06213 | 1/20 | 0.45 |
| ▸ | NPM1 | P06748 | 1/20 | 0.45 |
| ▸ | CSF1R | P07333 | 1/20 | 0.45 |
| ▸ | LYN | P07948 | 1/20 | 0.45 |
| ▸ | IGF1R | P08069 | 1/20 | 0.45 |
| ▸ | MET | P08581 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5117330 | 0.84 | EGFR (0.81) | EGFRTEKERBB2ERBB3ERBB4 | |
| SCHEMBL5112844 | 0.83 | EGFR (0.80) | EGFRTEKERBB2ERBB3ERBB4 | |
| SCHEMBL5113829 | 0.82 | EGFR (0.79) | EGFRTEKERBB2ERBB3ERBB4 | |
| SCHEMBL5123499 | 0.82 | EGFR (0.79) | EGFRTEKERBB2ERBB3ERBB4 | |
| SCHEMBL5116554 | 0.81 | EGFR (0.77) | EGFRTEKERBB2ERBB3ERBB4 | |
| SCHEMBL5122500 | 0.80 | EGFR (0.75) | EGFRTEKERBB2ERBB3ERBB4 | |
| SCHEMBL5116929 | 0.80 | EGFR (1.00) | EGFRTEKERBB2ERBB3ERBB4 | |
| SCHEMBL5115691 | 0.79 | EGFR (0.75) | EGFRTEKERBB2ERBB3ERBB4 | |
| SCHEMBL5117360 | 0.79 | EGFR (0.75) | EGFRTEKERBB2ERBB3ERBB4 | |
| SCHEMBL5117302 | 0.79 | TEK (0.72) | EGFRTEKERBB2ERBB3ERBB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7435739-B2 | Substituted pyrrolopyrimidines useful in the treatment of cancer | CHEN JINSHAN | 2008-10-14 | — | — | US | claimed |
| JP-2007511596-A | — | — | 2007-05-10 | — | — | JP | claimed |
| EP-1687309-A1 | PYRROLOPYRIMIDINE COMPOUNDS USEFUL IN TREATMENT OF CANCER | Pfizer Products Inc. (US) | 2006-08-09 | — | — | EP | claimed |
| US-20050130994-A1 | Pyrrolopyre compounds useful in treatment of cancer | PFIZER INC | 2005-06-16 | — | — | US | claimed |
| WO-2005047289-A1 | PYRROLOPYRIMIDINE COMPOUNDS USEFUL IN TREATMENT OF CANCER | PFIZER PRODUCTS INC. (US) | 2005-05-26 | — | — | WO | claimed |
| US-7435739-B2 | Substituted pyrrolopyrimidines useful in the treatment of cancer | CHEN JINSHAN | 2008-10-14 | — | — | US | disclosed |
| EP-1687309-A1 | PYRROLOPYRIMIDINE COMPOUNDS USEFUL IN TREATMENT OF CANCER | Pfizer Products Inc. (US) | 2006-08-09 | — | — | EP | disclosed |
| US-20050130994-A1 | Pyrrolopyre compounds useful in treatment of cancer | PFIZER INC | 2005-06-16 | — | — | US | disclosed |
| WO-2005047289-A1 | PYRROLOPYRIMIDINE COMPOUNDS USEFUL IN TREATMENT OF CANCER | PFIZER PRODUCTS INC. (US) | 2005-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130994-A1 | Pyrrolopyre compounds useful in treatment of cancer | TP53, CCNT1, CCNE1 | EGFR 2127/4885TEK 2316/4885ERBB2 2484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.